Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00644553 · ClinicalTrials.gov registry record · Phase 3

Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis

A Phase 3 study, sponsored by Abbott.

Completed
Registry status
Phase 3
Development phase
437
Enrollment target

NCT00644553 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 437 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00644553, a Phase 3 study, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 3
Development phase
437 participants
Enrollment target

Study Summary

To compare the safety/tolerability and efficacy of a 14-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 14-day course of amoxicillin-clavulanate tablets (875/125 mg BID) for the treatment of ambulatory subjects with Acute Bacterial Sinusitis (ABS).

Interventions

  • DRUG Amoxicillin
  • DRUG Clarithromycin

Trial Details

FieldValue
Enrollment Target 437 participants
Start Date 2003-05
Phase Phase 3

Sponsor

Abbott

181 total trials

What the Registry Record Tells You About NCT00644553

The ClinicalTrials.gov registry entry for NCT00644553 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Amoxicillin is the first listed.

NCT00644553 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00644553 about?

NCT00644553 is a clinical study titled "Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis". To compare the safety/tolerability and efficacy of a 14-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 14-day course of amoxicillin-clavulanate tablets (875/125 mg BID) for the treatment of ambulatory subjects with Acute Bacterial Sinusitis (ABS).

What is the current status of trial NCT00644553?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2003-05.

What interventions are being tested in trial NCT00644553?

The interventions under investigation include: Amoxicillin (DRUG), Clarithromycin (DRUG).

Who is sponsoring clinical trial NCT00644553?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.